Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05549466
Other study ID # SYSUCC-CMY-2022-0917
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 8, 2022
Est. completion date September 20, 2025

Study information

Verified date February 2023
Source Sun Yat-sen University
Contact Ming-Yuan Chen, MD, PhD
Phone 86-20-8734-3361
Email chmingy@mail.sysu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients. How to deal with the ICIs resistance is an urgent problem in clinical practice. Based on previous clinical trials, anti-angiogenic drugs combined with immunotherapy were found to be effective. Therefore, this study intends to preliminarily evaluate which treatment regimen can provide the most benefit to PD-1 inhibitor refractory patients by comparing the efficacy of VEGFR inhibitor or standard chemotherapy combined with PD-1 inhibitor.


Recruitment information / eligibility

Status Recruiting
Enrollment 84
Est. completion date September 20, 2025
Est. primary completion date September 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Male or female; 18-70 years of age; 2. Had histopathologically confirmed nonkeratinizing recurrent/metastatic NPC (AJCC, 8th; the metastatic tissue biopsy is preferred, not necessary). 3. ECOG performance status of 0 or 1. 4. Progression after previous treatment with platinum-based dual-drug chemotherapy. 5. Progression after previous treatment with PD-1 inhibitors. 6. Experieced at least 1 line systemic therapy. 7. Subjects enrolled must have measurable lesion(s) according to response evaluation criteria in solid (RECIST) v1.1. 8. Adequate organ function assessed by laboratory parameters during the screening period 9. Life expectancy more than 12 weeks. 10. Able to understand and sign an informed consent form (ICF). Exclusion Criteria: 1. Recurrent lesions suitable for radical treatment (radiotherapy or surgery). 2. Previous treatment over 2 lines. 3. Patients who had previously received one of the three chemotherapy drugs and were randomly assigned to single-agent chemotherapy (control group) were not eligible to reuse the same treatment in this study. In addition, patients who had previously received all three chemotherapy agents for R/M lesions were excluded from the study. 4. Prior use of any anti-VEGF(R) agents. 5. Patients with other malignancies. 6. Patients with nasopharyngeal necrosis found by endoscope before enrollment or with a > 50% chance of nasopharyngeal necrosis according to the risk prediction model: ? Patients with recurrent stage T3-4 received two courses of radiotherapy before enrollment, or received nasopharyngeal radiotherapy within 1 year before enrollment; ? Patients with recurrent T1-2 stage had received two courses of radiotherapy and nasopharyngeal radiotherapy within 1 year before enrollment. 7. Patients with or previous with serious hemorrhage (bleeding >30 ml within 3 months), haemoptysis (> 5 ml within 4 weeks) of thromboembolic events within 12 months (including stroke events and/or transient ischemic attack). 8. Patients with hypertension who cannot be reduced to the normal range by antihypertensive drug treatment (systolic blood pressure > 140 mmHg/diastolic blood pressure > 90 mmHg), patients with = grade II coronary heart disease, arrhythmia (including QTc interval prolongation > 450 ms in men and > 470 ms in women) and cardiac insufficiency. 9. Patients with known or suspected autoimmune diseases including dementia and seizures. 10. Multiple factors affecting the absorption of oral medications (e.g., dysphagia, chronic diarrhea, and bowel obstruction). 11. An excessive dose of glucocorticoids given within 4 weeks before enrollment. 12. Complications requiring long-term use of immunosuppressive drugs or systemic or local use of immunosuppressive-dose corticosteroids. 13. Patients with active pulmonary tuberculosis (TB) receiving anti-TB treatment or who have received anti-TB treatment within 1 year prior to screening. 14. HIV positive; HBsAg positive and HBV DNA copy number positive (quantitative detection = 1000 cps/ml); chronic hepatitis C with blood screening positive (HCV antibody positive). 15. Any anti-infective vaccines such as influenza vaccine, varicella vaccine, etc., within 4 weeks before enrollment. 16. Women of childbearing age with a positive pregnancy test and lactating women. 17. Special attention: Patients with active bleeding, ulcers, and bowel perforations within 30 days after major surgery with tumors in close proximity to the internal carotid artery or other major vessels, and those at risk of major bleeding are prohibited. 18. Patients considered unsuitable for inclusion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
Gemcitabine, iv, 1000 mg/m^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m^2, D1, Q3W. Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.
Apatinib, Camrelizumab
Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.
Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
Gemcitabine, iv, 1000 mg/m^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m^2, D1, Q3W. Camrelizumab, iv, 200mg, D1, Q3W.
Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
Gemcitabine, iv, 1000 mg/m^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m^2, D1, Q3W.

Locations

Country Name City State
China Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate (ORR) Objective response rate is the rate of patients achieving complete response or partial response for a certain period of time after intervention. 1 year
Secondary Median progression-free survival (PFS) Progression-free survival is calculated from the date of randomization to the date of death of any cause or the first progress at any site, censored on the last date of tumor evaluation if no progress has happened. 3 years
Secondary Median overall survival (OS) Overall survival is calculated from the date of randomization to the date of death of any cause, censored on the last date of known survival if no death has happened. 3 years
Secondary Duration of response (DoR) Defined as the time from first documentation of objective response to radiological disease progression. 3 years
Secondary Disease control rate (DCR) Disease control rate is the rate of patients achieving complete response, partial response or stable disease for at least 4 weeks after intervention. 1 year
Secondary Adverse events NCI-CTC5.0 and RTOG standards are adopted, and acute subjective toxicity, acute objective toxicity and late subjective toxicity are included. 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05979961 - Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT06055816 - Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma Phase 2
Recruiting NCT05547971 - Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
Not yet recruiting NCT05020925 - SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 1/Phase 2
Not yet recruiting NCT04547088 - Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Not yet recruiting NCT04548271 - Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02795169 - Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02801487 - Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02569788 - Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Completed NCT02237924 - Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02044562 - Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients N/A
Terminated NCT01694576 - NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation Phase 2
Recruiting NCT01462903 - A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors Phase 1
Completed NCT01271439 - Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma Phase 2
Completed NCT00535795 - Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Phase 3
Completed NCT00379262 - Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma Phase 3
Completed NCT03398980 - Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy N/A
Completed NCT01309633 - Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) Phase 2